Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Eculizumab and Ravulizumab Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Currently Treated With Eculizumab or Ravulizumab
Conditions
Interventions
Cemdisiran
Eculizumab
+2 more
Locations
1
United States
Regeneron Research Facility
Whittier, California, United States
Start Date
October 6, 2022
Primary Completion Date
July 12, 2023
Completion Date
July 12, 2023
Last Updated
April 8, 2025
NCT03520647
NCT04645199
NCT07152288
NCT06411626
NCT06298955
NCT05389449
Lead Sponsor
Regeneron Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions